GIVING SOLUTIONS

Since 2006 BMG Pharma specializes in developing and partnering speciality pharmaceutical medical devices, food supplements and cosmetics.

NEWS

Presentation of new GelX® data at the forthcoming CPHi Worldwide Congress, 25th October 2017.

Presentation of new GelX® data at the forthcoming CPHi Worldwide Congress, 25th October 2017.

July 10th 2017 Milan, Italy: BMG Pharma S.r.l., an innovative specialty pharmaceutical company, announces it will be presenting significant newly generated
Read More
Milan, Italy: Pierre Fabre Pharmaceuticals and BMG Pharma S.r.l announce the signature of a Distribution and Supply Agreement for AFTACURE Gel and AFTACURE Spray in different territories
Milan, Italy: BMG PHARMA S.r.l announces the  achievement of the Certificate for ISO 13485.

Milan, Italy: BMG PHARMA S.r.l announces the achievement of the Certificate for ISO 13485.

January 18th 2016 BMG Pharma S.r.l. is pleased to announce the achievement of the ISO Certificate 13485 from TÜV Süd. The Certificate
Read More
Milan, Italy: BMG PHARMA S.r.l announces the issue of results of clinical studies related to its proprietary products GelX oral Gel and GelX Oral Spray.

Milan, Italy: BMG PHARMA S.r.l announces the issue of results of clinical studies related to its proprietary products GelX oral Gel and GelX Oral Spray.

November 9th 2015 BMG Pharma S.r.l. is pleased to announce the publication of results of clinical studies related to GelX® Oral
Read More
BMG PHARMA S.r.l announces the signature of a Distribution Agreement for its Cancer Supportive Care line including its iron in liposomal technology based product with Sayre Therapeutics for India and other Asian area countries.
BMG PHARMA S.r.l  announces the signature of a Distribution Agreement for its proprietary product IALUXID® Gel with LatAm HQ Health Ltd, UK for the territory of Central and South  America. LatAm HQ will also launch in the same territory  other BMG proprietary products such as AKENKIT and  NASAL SPRAY SOLUTIONS.
BMG Pharma S.r.l (“BMG”) announces the launch of its proprietary product Ialuxid® Gel under the new trademark HPO Skin Protect owned by Centro Internacional de Cosmiatria, S.A.P.I. de C.V. (“FARMAPIEL”) in Mexico.
BMG PHARMA S.r.l. announces the launch of its proprietary product Ialuxid® Gel in the People’s Republic of China by Luqa Pharmaceuticals.

BMG PHARMA S.r.l. announces the launch of its proprietary product Ialuxid® Gel in the People’s Republic of China by Luqa Pharmaceuticals.

March 10th 2015 BMG Pharma S.r.l. is today pleased to announce the launch of its proprietary product Ialuxid® Gel in the
Read More
Milan, Italy: BMG PHARMA S.r.l  obtained a new indication on Molluscum Contagiosium for CE marked proprietary product Ialuxid® Gel.

Milan, Italy: BMG PHARMA S.r.l obtained a new indication on Molluscum Contagiosium for CE marked proprietary product Ialuxid® Gel.

February 9th 2015 BMG Pharma S.r.l. today is pleased to announce that it has obtained the inclusion of the Molluscum Contagiosum in
Read More
BMG PHARMA S.r.l grants the exclusive distribution rights for GelX® Oral Gel and GelX® Spray for the treatment of oral mucositis in cancer patients to FERRER INTERNACIONAL  S.A.

BMG PHARMA S.r.l grants the exclusive distribution rights for GelX® Oral Gel and GelX® Spray for the treatment of oral mucositis in cancer patients to FERRER INTERNACIONAL S.A.

January 19th 2015 BMG Pharma S.r.l. (BMG) today is pleased to announce that it has signed an exclusive distribution agreement with
Read More